Difference between revisions of "Desmoid tumor"
Jump to navigation
Jump to search
Line 47: | Line 47: | ||
!style="width: 33%"|Years of enrollment | !style="width: 33%"|Years of enrollment | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2006.08.2966 Skapek et al. 2007 (POG 9650)] | ||
+ | |1997-2001 | ||
+ | | style="background-color:#91cf61" |Phase II | ||
|- | |- | ||
|[https://doi.org/10.1016/s1470-2045(19)30276-1 Toulmonde et al. 2019 (DESMOPAZ)] | |[https://doi.org/10.1016/s1470-2045(19)30276-1 Toulmonde et al. 2019 (DESMOPAZ)] | ||
Line 60: | Line 64: | ||
'''7-day cycle for 26 cycles, then 14-day cycle for 13 cycles''' | '''7-day cycle for 26 cycles, then 14-day cycle for 13 cycles''' | ||
===References=== | ===References=== | ||
+ | #'''POG 9650:''' Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10;25(5):501-6. [https://doi.org/10.1200/jco.2006.08.2966 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/17290057/ PubMed] | ||
#'''DESMOPAZ:''' Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. [https://doi.org/10.1016/s1470-2045(19)30276-1 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/31331699/ PubMed] NCT01876082 | #'''DESMOPAZ:''' Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. [https://doi.org/10.1016/s1470-2045(19)30276-1 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/31331699/ PubMed] NCT01876082 | ||
Revision as of 23:21, 6 November 2021
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ![]() |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
5 regimens on this page
7 variants on this page
|
All lines of therapy
Doxorubicin pegylated liposomal monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Constantinidou et al. 2009 | 2006-2009 | Case series |
Chemotherapy
- Pegylated liposomal doxorubicin (Doxil) 50 mg/m2 IV over 60 minutes once on day 1
28-day cycles
References
- Case series: Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4. Epub 2009 Sep 18. link to original article PubMed
Methotrexate & Vinblastine
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Skapek et al. 2007 (POG 9650) | 1997-2001 | Phase II |
Toulmonde et al. 2019 (DESMOPAZ) | 2012-2017 | Randomized Phase II |
Note: this study was randomized but non-comparative.
Chemotherapy
- Methotrexate (MTX) 30 mg/m2 IV once on day 1
- Vinblastine (Velban) 5 mg/m2 IV once on day 1
7-day cycle for 26 cycles, then 14-day cycle for 13 cycles
References
- POG 9650: Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10;25(5):501-6. link to original article contains verified protocol PubMed
- DESMOPAZ: Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. link to original article contains protocol PubMed NCT01876082
Imatinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Kasper et al. 2017 (GISG-01) | 2010-2013 | Phase II |
Targeted therapy
- Imatinib (Gleevec) 800 mg PO once per day
2 years of therapy
References
- GISG-01: Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017 May;76:60-67. Epub 2017 Mar 8. link to original article contains verified protocol PubMed NCT01137916
Pazopanib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Toulmonde et al. 2019 (DESMOPAZ) | 2012-2017 | Randomized Phase II |
Note: this study was randomized but non-comparative.
Targeted therapy
- Pazopanib (Votrient) 800 mg PO once per day
Up to 12 months of therapy
References
- DESMOPAZ: Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep;20(9):1263-1272. Epub 2019 Jul 19. link to original article contains protocol PubMed NCT01876082
Sorafenib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Gounder et al. 2018 (Alliance A091105) | 2014-2016 | Phase III (E-esc) | Placebo | Superior PFS |
Targeted therapy
- Sorafenib (Nexavar) 400 mg PO once per day
Continued indefinitely
References
- Alliance A091105: Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20;379(25):2417-2428. link to original article contains protocol link to PMC article PubMed NCT02066181